Opinion|Videos|November 4, 2024
Complement Inhibitors for Treatment of Generalized Myasthenia Gravis
Key Takeaways
- Complement inhibitors target the C5 component of the complement cascade, preventing membrane attack complex formation and reducing neuromuscular junction damage.
- Clinical trials show significant efficacy in improving muscle strength and reducing symptoms in gMG patients.
Panelists discuss how complement inhibitors work to treat generalized myasthenia gravis (gMG), evaluating their efficacy and safety profiles based on FDA approvals and clinical experience.
Advertisement
Video content above is prompted by the following:
- Complement inhibitor agents have been approved by the FDA for treatment of gMG. Provide an overview of their mechanism of action and your overall impressions of the efficacy and safety of these agents.
Advertisement
Related to this article
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
New 12-month interim data showed functional gains with BBP-418 vs placebo, consistent benefit across genotype, age, and baseline pulmonary function subgroups, and a safety profile comparable to placebo.
Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.
A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.
A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.
PETUNIA, a new global pharmacovigilance study, will track pregnancy, maternal, and infant outcomes among patients with gMG exposed to nipocalimab.
In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.
Findings from the phase 1/2 RESET-MG trial, presented at AANEM 2026, showed that 10 of 13 patients with refractory generalized myasthenia gravis had clinically meaningful MG-ADL improvements after a single infusion of rese-cel.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP
4
Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab
5